Ph.D. Michael Exton - 28 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: LXRX
Reported as of: 28 Feb 2026
Net transaction value: -$301,102
SEC form: 4
Accepted by SEC: 03 Mar 2026, 07:15:34 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Exton, Ph.D.

Key filing fact

Ph.D. Michael Exton filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 03 Mar 2026.

Key facts

This page summarizes Ph.D. Michael Exton's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 07:15.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: -$301,102.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002029249 Primary reporting owner

Exton Michael

Relationship: Chief Executive Officer, Director
Address: 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, THE WOODLANDS
Signature: /s/ Michael Exton, Ph.D.
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +503,263
Change %
Price
Shares after: 503,263
Date: 28 Feb 2026
Ownership: Direct
Footnotes: F1

LXRX transaction

Common Stock

Tax liability

Transaction value: $301,102
Shares: -204,831
Change %: -41%
Price: $1.47
Shares after: 298,432
Date: 28 Feb 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXRX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -503,263
Change %: -33%
Price
Shares after: 1,006,527
Date: 28 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 503,263
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F2

Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

Footnote F3

Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.